Showing results (2631-2640 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|October 19, 2015
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMunira Essat, Paul Tappenden, Shijie Ren, et al.
Pharmacoeconomics|May 18, 2019
Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)Hui Shao, Vivian Fonseca, Charles Stoecker, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Pharmacoeconomics|April 27, 2019
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and AssumptionsMarina Treskova, Stefan M Scholz, Alexander Kuhlmann
Pharmacoeconomics|July 28, 2018
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort ModelsAnthony J Hatswell, Ash Bullement, Andrew Briggs, et al.
Pharmacoeconomics|October 19, 2021
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|October 1, 2021
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature ReviewThitima Kongnakorn, Grammati Sarri, Andreas Freitag, et al.
Pharmacoeconomics|October 8, 2021
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare PerspectiveAdnan Alsumali, Laurence M Djatche, Andrew Briggs, et al.
Pharmacoeconomics|October 12, 2021
Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable WorkshopJamie Elvidge, Dalia Dawoud
Pharmacoeconomics|September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 PandemicYumi Asukai, Andrew Briggs, Louis P Garrison, et al.
Pageof 336